Castelli MC, Wong DF, Friedman K, Riley MG
Reducing the Risk of Cardiovascular Events A multicenter, randomized trial found that in patients with cardiovascular disease and overweight or obese but without diabetes, a weekly dose of 2.4 mg Semaglutide was more effective than a placebo in reducing deaths from cardiovascular causes, nonfatal heart attacks, and nonfatal strokes over an average follow-up period of 39.8 months
That is why driving after THC gummies is not safe
They are a popular alternative for patients that are uncomfortable with self-injections
Expert medical care: Our highly trained medical team is dedicated to your safety and success
Ozempic, Wegovy Vision Change Side Effects May Leave Users With Blurred Sight, Blindness: Study The risk of Ozempic and Wegovy vision changes were seven times higher than for patients who took non-semaglutide drugs for diabetes and weight loss